Anaxis Pharma

Life sciences investor MTPConnect injects $12 million into 14 drug and device startups

MTPConnect's government-backed accelerator program has awarded $12.07 million in non-dilutive grants to 14 Australian drug and device companies, which will also receive mentoring and support from partners including CSL and Roche Diagnostics.

Also SmartCompany·@AuManufacturing

Professor got nothing from the $2.8b sale of his molecule, and that's okay

Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.

Scientist behind Australia’s highest-priced molecule reveals how to profit from early stage biotechs

Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.

Also Forbes Australia

SYNthesis BioVentures - Newsletter no. 1

Debut quarterly letter from SYNthesis BioVentures reporting A$18 million committed to its fund, an A$3.8 million stake in Catalyst Therapeutics' A$11.7 million seed round, and two senior appointments from the SYNthesis Group.